Cumberland概述将运营资金延长至五年以上的计划，同时准备为ifetroban治疗杜氏肌营养不良症（DMD）提交滚动新药申请（NASDAQ:CPIX）
· seekingalpha.com
Cumberland Pharmaceuticals报告第三季度净利润7780万美元，持有8060万美元现金且无负债。
Earnings Call Insights Cumberland outlines plan to fund operations for over 5 years as it prepares rolling NDA submission for ifetroban in DMD Nov 10, 2026, 6:4...